Blog / Clorox (CLX) and Church & Dwight (CHD) versus Amgen (AMGN) and Bristol-Myers Squibb (BMY)

Clorox (CLX) and Church & Dwight (CHD) versus Amgen (AMGN) and Bristol-Myers Squibb (BMY)

4 Sagging Dividend Growth Stocks 2 Are Buys 2 Are Not

Clorox
Clorox, Church & Dwight, Amgen, Bristol-Myers

Clorox, Church & Dwight, Amgen, Bristol-Myers

Many high-quality dividend growth stocks have recently experienced substantial drops in their prices. When the price of a common stock drops, investors will almost assuredly ask me if I like it better now. In fact, it is one of the most asked questions after a price drop that I get asked. However, the answer is always – it depends. As I often state, measuring performance without simultaneously measuring valuation is a job half done. Therefore, just because the price of the stock drops does not automatically mean that the company has become an attractive purchase. This is especially true with significantly overvalued stocks. I recently went through the S&P 500 and I have noticed many companies have experienced price drops recently. Unfortunately, the majority have fallen from already overvalued territory. Therefore, even though they are slightly less expensive than they were previously, they remain dramatically overvalued. The moral of the story is base your stock investment decisions on fundamental values rather than short-term price activity. With this video I will examine several companies that have all had price drops but from different valuation levels.

In this video I will review dividend growth stocks Clorox (CLX), Church & Dwight (CHD), Amgen (AMGN) and Bristol-Myers Squibb (BMY)

FAST Graphs Analyze Out Loud Video

Try FAST Graphs for FREE Today!

SUBSCRIBE to our YouTube Channel

Click here for our Research Articles

Disclosure: Long AMGN, BMY at the time of writing.

Disclaimer: The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients. Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted. The information in this document is believed to be accurate, but under no circumstances should a person act upon the information contained within. We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation.